|
413 Outrage
over Pfizer's distribution announcement Pfizer last week announced
that it will sell its products in the UK with UniChem acting as sole
distributor in a bid to secure the supply chain against counterfeit medicines.
The move has outraged community pharmacy bodies and many doubt Pfizer's
motivations
PJ 2006;277:413
Full Text
413 Supplementary
prescribers need more support, survey finds Pharmacist supplementary
prescribers need more support in terms of infrastucture and in becoming
better integrated into the health care team, according to the authors
of a paper
PJ 2006;277:413
Full Text
414 Well
educated women could be adding to antimicrobial resistance There is an association between keeping leftover antimicrobials — including all antibiotics and antifungals — for future use and being educated and knowledgeable about these drugs, according to a survey of almost 7,000 households in the UK
PJ 2006;277:414
Full Text
414 Society’s OTC
statin guidelines criticised Guidelines for over-the-counter statin
treatment produced by the Royal Pharmaceutical Society could lead to under-treatment
of high risk individuals and unnecessary treatment for people at low risk of
heart disease, according to the authors of a letter published in the BMJ
PJ 2006;277:414
Full Text
414 Flu vaccine campaign
starts in Scotland This week saw the start of the annual influenza
immunisation campaign in Scotland. But launching the campaign, Scotland's chief
medical officer, Harry Burns, acknowledged that delivery of vaccines had been
delayed by approximately one month
PJ 2006;277:414
Full Text
414 Advice deemed as effective
as drugs for patients with medicines overuse headache Advice is as
effective as medication for the treatment of medicines overuse headache, an Italian
study suggests
PJ 2006;277:414
Full Text
414 RNA interference discovery
wins US researchers the Nobel Prize for medicine Two US scientists
have been awarded the Nobel Prize for medicine for their discovery of RNA interference,
a mechanism for silencing genes that could lead to the development of new treatments
PJ 2006;277:414
Full Text
414 MHRA intervenes on “two for one” A
complaint by Boots The Chemists about Tesco's multiple purchase offer on Resolve
and Resolve Extra has been upheld by the Medicines and Healthcare products Regulatory
Agency
PJ 2006;277:414
Full Text
415 Government
needs to ensure commissioning is fair Central government needs to
send out clear signals that a level playing field must be established for commissioning
primary care services, the National Pharmacy Association has urged
PJ 2006;277:415
Full Text
415 Schizophrenia drugs
must be better managed Management of medicines for people with schizophrenia
needs to improve, the Healthcare Commission has insisted
PJ 2006;277:415
Full Text
415 Pharmacists are key
to supporting work of primary care trusts Pharmacists are a key group in supporting primary care trusts' efforts to deliver community health care services to local patients, the NHS Confederation says in its report “Primary care trusts: serving communities”
PJ 2006;277:415
Full Text
415 Pharmacy included
in DoH review of urgent care services Services provided by pharmacists
are among those included in a Department of Health discussion document on urgent
care launched by health minister Lord Warner this week
PJ 2006;277:415
Full Text
415 BOC home oxygen supplies BOC
has now ceased supplying home oxygen cylinders to pharmacies in: South East London,
Kent, Surrey and Sussex; South West London, Thames Valley, Hampshire and Isle
of Wight; Eastern England; and North East England
PJ 2006;277:415
Full Text
415 Part 7 prices Changes
to the prices of drugs in part 7 of the Drug Tariff were made in Scotland from
1 October
PJ 2006;277:415
Full Text
416 Three-drug
combination improves disease-free progression in metastatic HER2+ breast cancer Adding
capecitabine (Xeloda) as a third chemotherapy agent to the most commonly used
first-line treatment for HER2-positive metastatic breast cancer significantly
increases time to progression, according to an international study giving the
first evidence of extra benefit with triple chemotherapy in this particularly
aggressive form of the disease
PJ 2006;277:416
Full Text
416 Adding anastrozole
to trastuzumab is beneficial in breast cancer Adding hormonal therapy
with anastrozole (Arimidex) to the HER2-receptor blocker trastuzumab (Herceptin)
doubles progression-free survival in women with metastatic breast cancer positive
for both hormone and HER2 receptors, according to the first study to look at
blocking both types of receptors
PJ 2006;277:416
Full Text
416 No harm delaying chemotherapy
for 12 weeks Adjuvant chemotherapy that starts up to 12 weeks after
surgery for breast cancer is as effective as that starting less than four or
eight weeks after, a retrospective review suggests
PJ 2006;277:416
Full Text
416 Drug-eluting stents
not less safe, says MHRA Adverse incident reports on drug-eluting
stents do not support the suggestion that they are less safe than non-drug-eluting
stents, the Medicines and Healthcare products Regulatory Agency said last week
PJ 2006;277:416
Full Text
417 PDA
criticises Society's approach in draft fitness-to-practise rules Criticism
has been levelled at the Royal Pharmaceutical Society by the Pharmacists Defence
Association for the overall tenor of proposed fitness-to-practice rules
PJ 2006;277:417
Full Text
417 MSD suspended from
ABPI for three months Merck Sharp & Dohme Ltd has been suspended from the Association of the British Pharmaceutical Industry for at least three months
PJ 2006;277:417
Full Text
417 Industry-sponsored
reviews should be read with caution Industry-sponsored reviews draw
more favourable conclusions than Cochrane reviews of the same drug and so readers
should be wary of their conclusions, a study published online on 6 October concludes
PJ 2006;277:417
Full Text
417 Stalemate over scheme
to stifle parallel importing Both parallel importers and GlaxoSmithKline
have claimed victory in a European Court case over the legality of GSK's dual
pricing scheme in Spain
PJ 2006;277:417
Full Text
417 Three new pharmaceutical
products awarded honour Three UK Prix Galien gold medals for pharmaceutical
innovation have been awarded to new medicines this year
PJ 2006;277:417
Full Text
|
The
Pharmaceutical Journal